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Abstract  17 
Mycoplasma cynos is recognized as an emerging causative pathogen of canine infectious 18 
respiratory disease (CIRD) world-wide. The goal of this work was to develop a new open-source 19 
real-time PCR assay for M. cynos that performs well under standard real-time PCR conditions. 20 
Primers and probes were designed to target the M. cynos tuf gene, and the assay was evaluated on 21 
the ABI 7500 and QuantStudio OpenArray platforms. The M. cynos tuf gene assay reaction 22 
efficiencies on 7500 and OpenArray platforms ranged from 94.3 to 97.9% and 119.1 to 122.5% 23 
(R2≥0.9935 and 0.9784) respectively, based on amplification of standard curves spanning 8 orders 24 
of magnitude. The assay performed very well over a range of template input, from 109 copies to 25 
the lower limit of quantitation at 4 copies of the M. cynos genome. Diagnostic performance was 26 
assessed by comparison of results with a legacy assay on clinical specimens as well as testing 27 
isolates that were previously characterized by intergenic spacer region sequencing. Exclusivity 28 
was established by testing 12 other veterinary Mycoplasma strains isolated from different animals. 29 
To substantiate the high specificity of the M. cynos tuf gene assay, sequence confirmation was 30 
performed on intergenic spacer region PCR amplicons. Further, whole genome sequencing of 31 
M.ycoplasma cynos and M.ycoplasma mucosicanis type strains are reported here for the first time. 32 
The complete sequences, protocol, and excellent performance of the newly developed M. cynos 33 
tuf assay is provided to facilitate assay harmonization. Additionally, the M. cynos tuf assay also 34 
performs very well on the OpenArray platform, enabling high-throughput testing capacity. 35 
 36 
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Introduction  38 
  Canine infectious respiratory disease (CIRD), also referred to as kennel cough, is a 39 
complex disease that can be caused by bacterial and/or viral pathogens such as Bordetella 40 
bronchiseptica, canine respiratory coronavirus (CRCoV), canine influenza virus (CIV), canine 41 
parainfluenza virus (CPIV), and canine pneumovirus (CnPnV).1,5,17  More recent studies and case 42 
reports have established an association between the presence of M. cynos and canine infectious 43 
respiratory disease world-wide.1,4,5,11,27  It is notable that no association was found between CIRD 44 
and 9 other Mycoplasma species found in the canine respiratory tract.1  45 
At least 17 Mycoplasma species have been detected in dogs, although at least half of these 46 
are also found in other mammalian hosts.1,2 Mycoplasma cynos was identified as a new 47 
Mycoplasma species of dogs by Rosendal in 1973.17 The type strain, deposited as Rosendal strain 48 
and subsequently designated H 831, was isolated from the lung of a dog with pneumonia,16 and 49 
additional M. cynos strains were isolated from respiratory and genital tracts of both healthy dogs 50 
and dogs with respiratory disease.17 M. cynos has been detected in samples from canine 51 
conjunctiva, nasal cavity, oral cavity, lower respiratory tract, genital tract, and urine.2,11,16,17 52 
Remarkably, M. cynos was also the only Mycoplasma species isolated from the air of a kennel.1 53 
Experimental infection of dogs with M. cynos can induce pneumonia.16,18  54 
Diagnostic testing for M. cynos can be performed with culture and/or molecular methods. 55 
M. cynos is a fastidious organism requiring complex growth media, and culture methods still 56 
require sequencing for species identification. Sequencing approaches used to date have been 57 
useful, but one cannot assume that all Mycoplasma species present are always detected.2,3 In an 58 
effort to improve molecular characterization of M. cynos, the genome sequence of strain C142 has 59 
been published,24 however little sequence information is available for type strain Rosendal/H 831 60 
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or other Mycoplasma species likely to be present in the same clinical specimen. There is need for 61 
a highly-specific and validated M. cynos real-time PCR assay to be published, including 62 
oligonucleotide sequences in order to allow for rapid results and assay harmonization. High 63 
specificity is imperative because it is not unusual for dogs to be infected with several Mycoplasma 64 
species simultaneously.1,2  65 
A legacy assay detecting the M. cynos 16S-23S rRNA intergenic (ITS) sequence was used 66 
in our laboratory prior to this work. However, that assay exhibited high variability in analytic 67 
performance on the QuantStudio 12K Flex OpenArray (OA) platform and this compelled us to 68 
develop a novel M. cynos MGB probe-based assay that would perform well under standard PCR 69 
and cycling conditions on both ABI 7500 and OA platforms, while providing high specificity on 70 
canine respiratory swab and tissue specimens. The OA platform was included in this test validation 71 
because it enables detection of respiratory pathogens in a high-throughput manner.9  72 
Materials and Methods 73 
Clinical specimens and reference strains 74 
For routine diagnostic testing, the starting amount used for purification is one nasal swab 75 
or 100-200 mg of tissue. Tissue samples are minced and combined with 1 mL DMEM 76 
(ThermoFisher Scientific, Waltham, MA) and then homogenized with a TissueLyser (Qiagen, 77 
Germantown, MD) for 2 minutes at 18 Hz. Following centrifugation at 3,000 rpm for 3 minutes, 78 
this supernatant is used for nucleic acid extraction. 79 
For determination of diagnostic specificity and sensitivity, 71 canine respiratory specimens 80 
submitted for routine canine respiratory panel diagnosis were tested with a legacy M. cynos assay 81 
(ITS) and the new M. cynos tuf assay. Additionally, 67 bacterial isolates previously characterized 82 
by Mycoplasma sSpp. culture and intergenic spacer region (ISR) sequencing for species 83 
Commentato [PM4]: Do we need to add the period? 
Page 5 of 26 
 
determination were tested with the new M. cynos tuf assay. This panel of bacterial isolates was 84 
comprised of M. canis, M. cynos, M. edwardii, M. felis, M. maculosum, and M. spumans strains. 85 
 Thirteen reference strains were tested to evaluate the analytical specificity of the assay, 86 
including Mycoplasma alkalesceans ATCC 29103, Mycoplasma arginini ATCC 23838, 87 
Mycoplasma bovigenitalium D0108 721, Mycoplasma bovigenitalium ATCC 19852, 88 
Mycoplasma bovirhinisaris ATCC 27748, Mycoplasma bovis D0200 473, Mycoplasma bovis 89 
ATCC 25523, Mycoplasma califorinicumason ST-6T or 6J Dellinger, Mycoplasma canadense 90 
ATCC 29418, Mycoplasma canis ATCC 19525, Mycoplasma cynos ATCC 27544, Mycoplasma 91 
edwardii ATCC 23462, and Mycoplasma mucosicanis ATCC BAA-1895. 92 
Positive amplification control 93 
 A positive amplification control (PAC) based on the tuf gene target region was 94 
synthesized and cloned by an ISO 9001:2008 certified facility (GenScript, Piscataway, NJ) and 95 
quantified using an intercalating dye (PicoGreen, ThermoFisher Scientific). The confirmed 96 
sequence is as follows:  97 
AGTGTTCCACGTTCAACACGTCCAGTAGCAACTGTTCCACGTCCTGTAATTGTAAAT98 
ACGTCCTCAACAGCCATTAAGAATGGTTTGTCATATTCTTTAACAGGTGTTTCAATAT99 
ATGAATCAACTGCGTCCATTAATTCTAATATTTTTTCTTCGTATTTAGCATCACCTTC100 
AAGTGCTTTTAAAGCTGAACCACGAATAATTGGCGCATTATCTCCATCAAATCCATA101 
TTCTGATAAAAGGCTACGAATTTCAACTTCAACTAATTCAATCATTTCTTCTTCACCT102 
TCTAACATATCAACTTTGTTTAAGAAAACAACGATACGCGGAACACCAACTTGTTTA103 
GATAAAAGAATGTGTTCACGTGTTTGAGGCATAGGCCCATCTGTTGCAGCAACAA. 104 
For high-throughput testing as part of a canine respiratory panel on the OA platform, a pool 105 
consisting of all positive amplification controls was created, including beta-coronavirus, 106 
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B.ordetella bronchiseptica, canine adenovirus, canine distemper virus, canine parainfluenza virus, 107 
canine pneumovirus, influenza A, M. cynos, and MS2 RNA phage.  108 
Nucleic acid extraction 109 
 Total nucleic acid (RNA and DNA) was purified with an automated magnetic bead-based 110 
extraction kit (MagMAX™ Total Nucleic Acid Isolation Kit AM1840, ThermoFisher Scientific). 111 
The purified nucleic acid was eluted in 90 µl.  112 
Exogenous internal control 113 
 We used the MS2 RNA phage as an exogenous internal control (XIC) by combining it with 114 
the MagMAX lysis buffer and detection in sample eluates.6 An acceptable range was established 115 
based on two standard deviations from the average cycle threshold (Ct) level in respiratory matrix, 116 
inclusive of tissues. PCR inhibition due to the sample matrix is indicated by the MS2 XIC signal 117 
being out of acceptable range or undetected. 118 
Assay design and amplification platforms  119 
 Primer Express software (Thermo Fisher Scientific) was used to design primers (forward 120 
5’ TCTTCGTATTTAGCATCACCTTCAAGT 3’; reverse 5’ TGATGGAGATAATGCGCCAAT 121 
3’), and an MGB probe (5’ FAM-CTTTTAAAGCTGAACCACG-MGB 3’) using an alignment of 122 
all available Mycoplasma species tuf gene sequences including M. cynos genome NC_019949.23  123 
 For the Applied Biosystems™ 7500 Real-Time PCR platform (Applied Biosystems, Foster 124 
City, CA), forward and reverse primers at 400 nM final concentration and probe at 120 nM final 125 
concentration were added to the Path-ID Multiplex One-Step RT-PCR master mix (Applied 126 
Biosystems) in 21µl and combined with 4 µl of template. Cycling conditions were 48°C for 10 127 
minutes, 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds then 60°C for 45 128 
seconds. 129 
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 For high-throughput testing, the new M. cynos tuf assay was also validated on the Applied 130 
Biosystems™ QuantStudio™ 12K Flex system with an OpenArray block (Thermo Fisher 131 
Scientific). This nanoscale diagnostic PCR workflow is optimized for use at Animal Health 132 
Diagnostic Center (AHDC) in our laboratory and has been described previously.9 Custom 133 
nanoscale PCR amplification plates arranged in an 18x3 gene expression format were ordered with 134 
the M. cynos tuf oligonucleotides listed above, in addition to oligonucleotides for other pathogen 135 
and control tests.9 The forward and reverse primers were also included in a pre-136 
amplification/reverse-transcription pool in combination with the other respiratory panel primers at 137 
9 M (Integrated DNA Technologies, Inc., Coralville, IA). This pool was combined with random 138 
primers at 300 nM final concentration (New England Biolabs, Ipswich, MA), TaqMan™ Fast 139 
Virus 1-Step Master Mix (Applied Biosystems), and 7 L template in a 10 uL total volume. Pre-140 
amplification cycling conditions were 50°C for 15 minutes, 95°C for 1 minute, 20 cycles of (95°C 141 
for 15 seconds and then 60°C for 2 minutes), followed by 99.9°C for 5 minutes in a conventional 142 
PCR machine. This pre-amplification product was then diluted in 40 L of 1X TE buffer. The pre-143 
amplified and diluted samples are then combined with an equal volume of TaqMan™ 144 
OpenArray™ Real-Time PCR Master Mix (Applied Biosystems), from which 33 nL is transferred 145 
to the nanoscale PCR amplification plate by the AccuFill system (Applied Biosystems). Note that 146 
the OA platform uses a different algorithm for calculating results called “CRT” (relative cycle 147 
threshold). Values are calculated based on the shape of individual amplification curves rather than 148 
the cycle of crossing a particular fluorescence threshold. For simplicity, herein we refer to CRT as 149 
Ct (cycle threshold), which is the value reported by the 7500 platform. 150 
 Routine controls were run in parallel to diagnostic samples, including a negative extraction 151 
control, negative amplification control, XIC (MS2 RNA phage), and PAC at 103 copies/µL.  152 
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Analytic Performance 153 
 A standard curve spanning 8 orders of magnitude was made from serial dilutions of the 154 
PAC. These dilutions were tested in triplicate on three different days. Amplification efficiency was 155 
calculated from the slope of the standard curve. Intra-assay variation was determined by 156 
calculating the percent coefficient of variation (%CV) from the replicates within each run. 157 
Interassay variation was determined by calculating the %CV from the replicates on different days. 158 
 The assay limit of detection (LOD) was calculated based on the mean of the Ct value at the 159 
lowest copy number where 100% of the replicates are positive plus 2 standard deviations. This 160 
was based on 12 replicates on the 7500 platform and 36 replicates on the OA platform. Platform-161 
specific interpretation ranges were established according to internal guidelines. For the 7500 162 
platform, Ct>LOD = “low positive”, Ct between LOD and the value of (LOD divided by 1.5) = 163 
“moderate positive”, Ct<(LOD divided by 1.5)  = “high positive”. For the OA platform, Ct>LOD 164 
= “low positive”, Ct between LOD and the value of (LOD divided by 2) = “moderate positive”, 165 
Ct<(LOD divided by 2)  = “high positive”. 166 
Diagnostic performance  167 
 A proprietary and internally approved legacy M. cynos ITS real-time PCR performed on 168 
the 7500 platform was chosen as the comparison method. Results of the legacy ITS assay were 169 
compared to results of the novel tuf assay using 71 canine respiratory specimens submitted for 170 
routine canine respiratory panel diagnosis. 171 
Sequencing of the 16S-23S rRNA ISR was chosen as the gold standard. PCR primers to 172 
amplify the ISR of Mycoplasma species were described previously.8 PCR products were visualized 173 
by gel electrophoresis. Initially, 5 L of PCR product were loaded on a 1.5% agarose gel and 174 
electrophoresed at 100 volts to observe the number of discrete bands present. GelRed nucleic acid 175 
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gel stain (Biotium, Fremont, CA) was used to stain DNA for visualization on a ChemiDoc Imaging 176 
system (Bio-Rad, Hercules, CA) with the accompanying Quantity One software. Amplicons were 177 
purified directly (QIAquick PCR Purification kit, Qiagen) or excised from the gel and purified 178 
with the QIAquick Gel Extraction Kit (Qiagen). The concentration of purified PCR products was 179 
determined by a Qubit 3.0 fluorometer (Thermo Fisher Scientific). Direct sequencing of amplicons 180 
was performed by the Institute of Biotechnology at Cornell University, Ithaca, NY. 181 
Chromatograms were visualized and manually edited with Geneious 8.1.7 182 
(https://www.geneious.com). Intergenic spacer region sequences obtained from clinical specimens 183 
were compared to Mycoplasma ISR sequences in the NCBI nucleotide collection database with 184 
BLAST. Phylogenetic analysis was performed with MEGA version X.12 185 
Results of canine respiratory specimens tested with the M. cynos tuf assay individually or 186 
as one of the canine respiratory panel assays were obtained from our laboratory information 187 
management system, from the time the tuf assay went into production to the present (October 7, 188 
2016 to February 14, 2019). This data was analyzed with Microsoft Access to quantify and 189 
characterize co-infection rates and pathogen prevalence. GraphPad Prism (GraphPad Software, 190 
San Diego, CA) was used to generate plots of the data. 191 
Whole Genome Sequencing 192 
 The MagMAX™ CORE Nucleic Acid Purification Kit (Applied Biosystems) was used to 193 
extract DNA from M. cynos (ATCC 27544) and M. mucosicanis (ATCC BAA-1895) type strains 194 
after enrichment. DNA was quantified with a Qubit 3.0 fluorometer (Thermo Fisher Scientific). 195 
The Nextera XT DNA Library Preparation Kit (Illumina, San Diego, CA) was used to prepare 196 
fragment libraries of the DNA for whole genome sequencing; this was performed according to the 197 
manufacturer’s instructions. Tagmented libraries were purified using AMPure XP Beads 198 
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(Beckman Coulter Life Sciences, Indianapolis, IN) at a concentration of 0.5x. Barcoded M. cynos 199 
and M. mucosicanis whole genome libraries were then pooled and run on Illumina MiSeq Reagent 200 
Kit (V3) cartridge at 2x250 cycles using a MiSeq next-generation sequencer. 201 
 Sequence reads were trimmed using the sliding window program in Trimmomatic with a 202 
window size of 4 and a minimum quality score of 20 [10.1093/bioinformatics/btu170]. Draft 203 
genomes were assembled using SPAdes 3.10.1 [10.1089/cmb.2012.0021]. Read depth and 204 
assembly statistics were calculated using BBMap 38.26 (https://jgi.doe.gov/data-and-205 
tools/bbtools/) and Quast 4.0 [10.1093/bioinformatics/btt086].  206 
The tuf gene was identified in each of the assemblies by running a BLASTN search against 207 
them using the tuf nucleotide sequence from the M. cynos C142 reference genome 208 
(HF559394.1:c930548-929361) [10.1186/1471-2105-10-421]. The tuf assay primer and probe 209 
sequences were also compared to our M. cynos and M. mucosicanis assemblies and to the published 210 
C142 genome. 211 
All sequences determined in this study have been submitted to NCBI BioProject XX (in 212 
process). 213 
Statistical analyses 214 
 GraphPad Prism (GraphPad Software) was used to analyze standard curve data by linear 215 
regression, coefficient of variation, and 2x2 test agreement analyses. 216 
 217 
Results 218 
Assay design and performance 219 
 Primers and probes for the tuf gene were designed based on alignment of M. cynos strains 220 
H 831 and C142 with 18 other Mycoplasma tuf gene sequences available on NCBI. 221 
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Standard curves with 8 orders of magnitude were run on three different days and analyzed 222 
by linear regression using GraphPad Prism (Table 1, Figure 1). The assay performance on the 7500 223 
platform using the master mix manufacturer’s recommended concentrations was linear (p = 0.21 224 
for deviation from linearity) with r2 ≥ 0.9935, and efficiency values of 94.3% to 97.9%. Dilutions 225 
of 0.1 and 0.01 copies per microliter were consistently not detected.  For the OA platform, 226 
amplification was also linear (p = 0.22 for deviation from linearity, Figure 1). The efficiency values 227 
ranged from 119.1% to 122.5%.  228 
 229 
Figure 1. Mycoplasma cynos standard curve dilution series. The Mycoplasma cynos positive 230 
amplification control was serially diluted and then amplified with the tuf assay on the ABI 7500 231 
and OpenArray platforms. Dilutions of 0.1 and 0.01 copies per uL were consistently not detected 232 
(not shown).  233 
 234 
Table 1. Standard curves demonstrating M. cynos tuf assay performance. 235 
Platform Day Slope R2  Efficiency 
7500 1 -3.467 ± 0.062 0.993 94.3% 
7500 2 -3.374 ± 0.056 0.994 97.9% 
7500 3 -3.437 ± 0.036 0.997 95.4% 
OA 1 -2.721 ± 0.050 0.986 122.5% 
OA 2 -2.762 ± 0.069 0.978 119.1% 
OA 3 -2.763 ± 0.049 0.989 119.7% 
 236 
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Repeatability  237 
 Intra-assay variation: On the 7500 platform (Table 2), all SDs were <1.0, and none of 238 
the CVs exceeded the maximum desired value of 3% (untransformed) or 50% (linearized using 239 
2-Ct). 240 
Table 2. Intra-assay variation of Cycle Threshold (Ct) values on the 7500 platform. 241 
Day Copies per µl Mean SD %CV (Ct) %CV (2-Ct) 
1 Low = 102 31.2 0.08 0.24 5.30 
1 Med = 103 27.7 0.05 0.16 3.14 
1 High = 104 24.4 0.10 0.39 6.53 
2 Low = 102 30.4 0.05 0.17 3.57 
2 Med = 103 27.0 0.07 0.27 5.21 
2 High = 104 23.6 0.04 0.19 3.06 
3 Low = 102 31.2 0.08 0.27 5.86 
3 Med = 103 27.9 0.10 0.38 7.25 
3 High = 104 24.5 0.06 0.24 4.06 
 242 
On the OA platform (Table 3), all SDs were <1.0. There were a number of failed CVs 243 
(>3%) using the untransformed values, but none of the CVs failed by the more appropriate 244 
linearized method (<50%). 245 
Table 3. Intra-assay variation of Cycle Threshold (Ct) values on the OA platform.  246 
Day Copies per µl Mean SD %CV (Ct) %CV (2-Ct) 
1 Low = 102 11.8 0.32 2.72 20.88 
1 Med = 103 9.0 0.27 2.98 16.75 
1 High = 104 5.8 0.27 4.70 17.32 
2 Low = 102 11.8 0.51 4.35 32.24 
2 Med = 103 8.7 0.32 3.69 20.72 
2 High = 104 5.7 0.47 8.30 34.19 
3 Low = 102 11.9 0.27 2.24 16.65 
3 Med = 103 8.8 0.28 3.20 16.98 
3 High = 104 5.9 0.29 4.91 17.22 
 247 
Inter-assay variation: Variation between runs on 3 different days is shown in Table 4. 248 
All SDs were <1.0, and none of the CVs exceeded the maximum desired value of 3% 249 
(untransformed) or 50% (linearized using 2-Ct). The slopes of the standard curves were not 250 
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significantly different on the three different days for each platform (p = 0.46 for 7500, p = 0.83 251 
for OA). 252 
Table 4. Inter-assay variation of Ct values. 253 
Platform Template concentration (per µl) Mean SD %CV (Ct) %CV (2-Ct) 
7500 Low = 102 30.9 0.49 1.60 36.7 
7500 Med = 103 27.5 0.49 1.79 35.9 
7500 High = 104 24.2 0.49 2.03 36.1 
OA Low = 102 11.9 0.05 0.44 5.3 
OA Med = 103 8.8 0.14 1.55 9.9 
OA High = 104 5.8 0.12 2.10 10.3 
 254 
Analytical sensitivity and specificity  255 
The analytical limit of quantitation was less than 10 copies of the bacterial genome on 256 
both platforms. This was based on 12 replicates on the 7500 platform and 36 replicates on the 257 
OA platform.  258 
To define the analytical specificity, the following Mycoplasma reference strains were 259 
tested and not detected with the M. cynos tuf assay: M. alkalescensalkalescans, M. arginini, M. 260 
bovigenitalium (D0108 721 and ATCC 19852), M. bovirhinis,bovirharis, M. bovis (D0200 473 261 
and ATCC 25523), M. califorinicumason, M. canadense, M. canis, M. edwardii, and M. 262 
mucosicanis. 263 
The positive amplification control run individually on the OA platform uniquely detected 264 
the new M. cynos tuf target, and no other targets from a panel of canine and equine respiratory 265 
assays; the latter was comprised of: beta-coronavirus, B.ordetella bronchiseptica, canine 266 
adenovirus, canine distemper virus, canine parainfluenza virus, canine pneumovirus, equine 267 
adenoviruses 1 and 2, equine herpesvirus 1 and 4, equine rhinitis viruses A and B, influenza A, 268 
Mycoplasma felis, Streptococcus equi, and Streptococcus zooepidemicus. Many of the clinical 269 
samples that were negative by the new tuf assay were positive for other pathogens including 270 
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beta-coronavirus, B.ordetella bronchiseptica, canine distemper virus, canine parainfluenza virus, 271 
canine pneumovirus, and influenza A virus. 272 
Diagnostic sensitivity and specificity  273 
 To assess the diagnostic sensitivity and specificity, 71 canine respiratory specimens 274 
submitted for routine diagnosis of canine respiratory disease were previously tested directly 275 
(without bacterial enrichment) with the legacy ITS assay and the new tuf assay. The new tuf assay 276 
demonstrated 95.77% agreement with legacy ITS assay (Table 5). The one false negative was most 277 
likely due to another Mycoplasma species being detected by the legacy assay as ISR sequencing 278 
revealed the presence of M. spumans in the sample. The other 2 discrepant samples were detected 279 
by the OpenArray but not the 7500 platform. The Kappa correlation for detection of canine 280 
respiratory specimens was 0.915 (95% confidence interval 0.822-1.000). 281 
Table 5. Diagnostic specificity assessment on canine respiratory samples. 282 
 ITS PCR + ITS PCR - 
tuf PCR + 33 2 
tuf PCR - 1 35 
 283 
 The diagnostic specificity of the new tuf assay was also assessed using 67 isolates that were 284 
characterized by Mycoplasma sSpp. culture and sequencing. The results identified 5 true positive 285 
isolates and 56 true negative isolates. The 56 negative samples were comprised of 22 M. canis 286 
isolates, 12 M. felis isolates, 12 M. spumans isolates, 7 M. edwardii isolates, and 3 M. maculosum 287 
isolates. No false negatives were found, although 6 isolates were determined to be false positives 288 
because they were positive with the tuf PCR assay but negative by ISR sequencing. Five of the 6 289 
discrepant ISR sequencing results had M. canis and M. edwardii as the two top BLAST hits but 290 
included M. cynos in the list of significant hits. ATCC isolates for M. canis and M. edwardii were 291 
tested and both yielded negative results with the tuf assay. The sixth discrepant isolate was typed 292 
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as M. maculosum or M. leopharyngis but also included many other significant hits including 293 
several that were excluded by testing the ATCC isolates listed above, thus we chose not to pursue 294 
this isolate further.  295 
 Inhibition monitoring 296 
 Continuous monitoring of the XIC did not reveal any systematic indications of inhibition 297 
in respiratory matrix, inclusive of tissues. Results from 22 clinical specimens tested on15 298 
independent ABI 7500 runs are shown in Figure 2. In these specimens, M. cynos Ct values ranged 299 
from 20.609 – 39.958 while the XIC Ct values ranged from 31.283 – 35.000. The OA assay 300 
detected a range of M. cynos Ct values (2.282 – 18.369) from 23 clinical specimens obtained from 301 
15 independent runs (Figure 3). The XIC was detected in the same specimens and with 302 
corresponding Ct values that remained within a span of 2 standard deviations (Ct range 10.694 – 303 
15.814; 2 standard deviation range10.682 – 16.164; Figure 3).  304 
 305 
Figure 2. Detection of Mycoplasma cynos target and exogenous internal control in clinical 306 
specimens on the ABI 7500 platform. Mycoplasma cynos was detected over a range of high, 307 
moderate, and low positive values (black diamonds; moderate positive range bracketed by black 308 
dotted line) in 22 clinical specimens. The MS2 exogenous internal control was detected in the 309 
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same specimens and MS2 Ct values remained within a span of 2 standard deviations (gray 310 
circles; 2 standard deviations represented by gray broken line).  311 
 312 
Figure 3. Detection of Mycoplasma cynos target and exogenous internal control in clinical 313 
specimens on the OpenArray platform.  A range of high, moderate, and low M.ycoplasma 314 
cynos positive values was detected in 23 clinical specimens (black diamonds; moderate positive 315 
range bracketed by black dotted line). The MS2 exogenous internal control was detected in the 316 
same specimens (gray circles; 2 standard deviations represented by gray broken line). 317 
Sequence confirmation 318 
 To confirm that tuf PCR positive specimens contained M. cynos, the intergenic spacer 319 
region (ISR) was amplified and sequenced. Amplification of the ISR was performed on 107 tuf 320 
PCR positive-specimens. Visualization of the ISR PCR products revealed that 89 tuf PCR positive-321 
specimens yielded a single ISR band at the 457 base pair size expected for the M. cynos genome. 322 
The remaining 18 tuf PCR positive-specimens yielded 2 bands; one at the size expected for the M. 323 
cynos genome and a second smaller band (Figure 4). Ninety-four PCR products were purified and 324 
were directly sequenced (91 of the amplicon size expected for M. cynos and 3 smaller). Of the 91 325 
amplicon sequences expected to be M. cynos, NCBI BLAST revealed that 82 were ≥99.6% 326 
identical to the M. cynos ISR sequence, one sequence shared high identity with M. mucosicanis 327 
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ISR sequence, and the remaining 8 had poor sequence quality that prevented definitive 328 
identification of the Mycoplasma species present in the specimen. The M. cynos 1642 strain 329 
genome sequence (HF559394) includes 3 discrete ISR, 2 of which are 257 bases in length and 330 
share 100% identity; the third ISR contains a 1 base insertion. Of the 82 sequences that matched 331 
M. cynos ISR sequence, 78 of these were 100% identical to the M. cynos 1642 strain ISR of 257 332 
bases (HF559394), 2 were 100% identical to the M. cynos 1642 strain ISR of 258 bases 333 
(HF559394), and 2 were 100% identical to the M. cynos 1642 strain ISR of 257 bases (HF559394) 334 
except each had an ambiguous (N) base that could not be manually resolved. The PCR sequence 335 
that shared high identity with M. mucosicanis strain 1642 sequence (FM180556.1) was identical 336 
at 307 of 309 ISR positions. Sequence analysis of the 3 smaller ISR PCR products identified the 337 
presence of M. spumans (100% identical to AF538684) and M. canadense (the most significant 338 
BLAST result was to AP014631 with 163 out of169 nucleotide  identities; these 2 PCR product 339 
sequences were identical to each other); these represent specimens with co-infection of at least 2 340 
Mycoplasma species. 341 
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 342 
Figure 4. Gel electrophoresis of Mycoplasma ISR PCR products. Most tuf PCR positive-343 
clinical specimens yielded a single Mycoplasma ISR band at the 457 base pair size expected 344 
(lanes 1 and 2) for the M. cynos genome. A subset of tuf PCR positive-clinical specimens yielded 345 
2 bands; one at the size expected for the M. cynos genome and a second smaller band (lanes 3 346 
and 4). Lane 5 contained the negative amplification control. The outermost lanes were loaded 347 
with 100 bp DNA ladder. 348 
 349 
 Phylogenetic analysis of the ISR sequences obtained in this work and from reference 350 
Mycoplasma strain sequences was performed. M. cynos ISR sequences from strain C142 and from 351 
sequence confirmation of tuf-PCR positive specimens (all 82 represented by sequence “Cornell 352 
ISR 1”) were placed within the M. synoviae cluster (Figure 5), consistent with previous reports of 353 
Page 19 of 26 
 
Mycoplasma phylogenetic analysis.3 Similarly, the ISR sequences from M. mucosicanis strain 354 
1642 and PCR sequencing herein were found in the M. bovis cluster. The remaining ISR sequences 355 
determined in this study, representing M. spumans and M. canadense, were present within the M. 356 
hominis cluster. 357 
 358 
Figure 5. Phylogenetic tree of Mycoplasma intergenic spacer region sequences. Evolutionary 359 
analyses were conducted in MEGA X and the tree was inferred using the Neighbor-Joining 360 
method.12,19 The bootstrap test with 1,000 replicates was used to determine the percentage of 361 
replicate trees in which the associated taxa clustered together and these values are shown next to 362 
the branches.7 Phylogenetic clustering of Mycoplasma strains are distinguished by color; 363 
sequences determined in this work are denoted by “Cornell ISR” prefix. Sequences identified 364 
multiple times are indicated by (#) following the name, with ‘#’ reflecting the number of times 365 
that sequence was obtained. Mycoplasma sequences obtained from GenBank include: A. 366 
laidlawii (CP000896), M. arginini (AY737013), M. bovigenitalium (AP017902), M. bovis 367 
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(CP002513), M. canadense (AY800341), M. canis (AF443605), M. cynos (NC_019949), M. 368 
edwardii (AF443607), M. felis (AF443608), M. gateae (AF443609), M. maculosum (AF443610), 369 
M. mucosicanis (FM180556), M. opalescens (AF443612), M. spumans (AF538684), and M. 370 
synoviae (AJ781002). The ISR sequence of Acholeplasma laidlawi was included as an outgroup. 371 
Whole genome sequencing 372 
 Our assembled M. cynos type strain Rosendal/H 831 (ATCC 27544) genome was 853,159 373 
bp with an N50 of 5,333 and a GC content of 26.35% (NCBI accession in process). Our M. 374 
mucosicanis type strain 1642 (ATCC BAA-1895) assembly consisted of 870,218 bp with an N50 375 
of 64,609 and GC content of 29.55% (NCBI accession in process). Average read depths were 15.4 376 
for M. cynos and 77.6 for M. mucosicanis. The M. cynos assembly shared 99.8% nucleotide 377 
identity (1186/1188 bases) with the C142 tuf sequence, while the M. mucosicanis shared 83.6% 378 
identity (999/1195 bases including 11 gaps). Our M. cynos assembly had exact matches to the tuf 379 
primer and probe sequences. The corresponding regions in our M. mucosicanis assembly shared 380 
23/27 nucleotide identities with the forward primer, 16/21 with the reverse primer, and 16/19 with 381 
the probe. Over the 72 bp region spanning the forward and reverse primers, our M. cynos assembly 382 
was identical to the C142 genome and our M. mucosicanis assembly had 13 variable sites. 383 
The ABI 7500 tuf gene assay was performed on the DNA extracted from the M. cynos and 384 
M. mucosicanis type strains obtained from ATCC and M. cynos was positive while M. mucosicanis 385 
was not detected.  386 
M. cynos prevalence and co-infections 387 
 Our laboratory has performed 1,982 M. cynos tuf tests on diagnostic canine respiratory 388 
specimens since initiating production of the new assay in late 2016, and of those, 634 (31.99%) 389 
were positive. In the same time frame, canine respiratory panel results were analyzed to investigate 390 
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M. cynos co-infections. The canine respiratory panel includes tests for beta-coronavirus, 391 
Bordetella bronchiseptica, canine adenovirus, canine distemper virus, canine parainfluenza virus, 392 
canine pneumovirus, and influenza A virus in addition to M. cynos. Of 1,368 canine respiratory 393 
panel tests, 358 (26.17%) results identified co-infections that included M. cynos. These co-394 
infections consisted of M. cynos plus another 1 (214 specimens, 59.78%), 2 (103 specimens, 395 
28.77%), 3 (28 specimens, 7.82%), 4 (10 specimens, 2.79%), or 5 (3 specimens, 0.84%%) 396 
pathogens (Figure 6A). The prevalence of pathogens present simultaneously with M. cynos in 397 
specimens was assessed, and canine parainfluenza virus was found most frequently (157 398 
specimens, 28.09%), followed by Bordetella bronchiseptica (119 specimens, 21.29%), and beta-399 
coronavirus (111 specimens, 19.86%). Also present less frequently in M. cynos co-infections were 400 
canine pneumovirus (84, 15.03%), canine distemper virus (41, 7.33%), influenza A virus (29, 401 
5.19%), and canine adenovirus (18, 3.22%) (Figure 6B). 402 
 403 
 404 
Figure 6. Number and prevalence of pathogens present in M. cynos co-infections. Panel A) 405 
Instances of 358 M. cynos co-infections since the tuf assay went into production consisted of 2 406 
(59.78%, white), 3 (28.77%, light gray), 4 (7.82%, gray), 5 (2.79%, dark gray), or 6 (0.84%, 407 
black) pathogens. Panel B) Co-infections included M. cynos and one or more of the following 408 
pathogens: canine parainfluenza virus (CPIV), 28.09%), Bordetella bronchiseptica (BB, 409 
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21.29%), beta-coronavirus (BCoV, 19.86%), canine pneumovirus (CnPnV, 15.03%), or canine 410 
distemper (CDV, 7.33%), influenza A (IAV, 5.19%), or canine adenovirus (CAV, 3.22%). 411 
Discussion 412 
The tuf assay described herein is intended for the diagnosis of M. cynos in canine 413 
respiratory samples with high specificity in a rapid and economical format that conforms to 414 
reagents and conditions commonly used in AAVLD laboratories. The validation data presented 415 
encompasses both the ABI 7500 and OA real-time PCR platforms. The tuf assay is compatible 416 
with the MS2 RNA phage XIC to facilitate PCR inhibition monitoring according to best practice 417 
guidelines of the AAVLD Technology Committee. Collectively, the performance of this assay 418 
meets the AAVLD guidelines and the authors’ internal validation standards. Additionally, use of 419 
this assay in our laboratory under ISO/IEC:17025 scope was approved by the American 420 
Association for Laboratory Accreditation (A2LA, certificate number 2880.01).  421 
To design a novel assay for M. cynos with high specificity, the gene encoding elongation 422 
factor Tu (tuf) was targeted because it contains Mycoplasma species-specific variable 423 
regions.14,20,22  The M. cynos tuf assay performed well on the ABI 7500 platform, even at very high 424 
template concentrations of up to 109 copies per microliter. On the OA platform, reaction 425 
efficiencies were high compared to typical benchmarks for the 7500 platform due to the fact that 426 
samples were pre-amplified and visualized using a white LED excitation source. Otherwise, the 427 
tuf PCR assay exhibited excellent performance and specificity on the OA platform; this attribute 428 
enables high-throughput testing and facilitates co-infection monitoring. The sequence 429 
confirmation data and phylogenetic analysis provide robust support for the specificity of the tuf 430 
PCR assay. The discrepant results identified between ISR sequencing and the new tuf assay, 431 
including the identification of M. mucosicanis in a tuf PCR positive-specimen, suggest instances 432 
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of mixed Mycoplasma infections. This was supported by the visualization of multiple bands upon 433 
ISR amplification, with 16.82% of tuf PCR positive-specimens producing 2 distinct ISR 434 
amplicons. Reference isolates of the other Mycoplasma species present in the sample, identified 435 
by ISR sequencing, were tested with the tuf assay and did not amplify. 436 
The ISR identity match of M. mucosicanis in a tuf PCR positive-specimen was of concern, 437 
and little is known about M. mucosicanis as it was recently identified.21 No full genome sequence 438 
was previously available for this species or for M. cynos type strain Rosendal/H 831. To address 439 
this, type strains of both M. mucosicanis and M. cynos were obtained from ATCC, and whole 440 
genome sequencing was performed in our laboratory. The whole genome and ISR sequence data 441 
determined here is publicly available to support efforts to better understand the clinical 442 
significance of Mycoplasma infection in canine health and to facilitate the identification of novel 443 
species. As Mycoplasma strains are able to cause disease directly as well as part of a co-infection, 444 
it is difficult to delineate their precise role. The association of this agent with morbidity in CIRD 445 
was previously characterized and is outside the scope of the present study. The high prevalence of 446 
close to one-third of clinical specimens being positive over two years of running the assay routinely 447 
is consistent with previous observations, which have largely focused on bacterial coinfections. The 448 
high proportion of viral co-infecting agents stresses the importance of comprehensive diagnostic 449 
testing for the management of CIRD, particularly in the context of AVMA guidelines for judicious 450 
use of antimicrobials (https://www.avma.org/KB/Policies/Pages/Judicious-Therapeutic-Use-of-451 
Antimicrobials.aspx). 452 
In some instances of dogs manifesting CIRD, co-infection of M. cynos with up to four other 453 
pathogens have been described. Pathogens identified in co-infections with M. cynos include 454 
Bordetella bronchiseptica, canine adenovirus type 2, canine distemper virus, and canine 455 
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parainfluenza virus.4,5,13 A review of our canine respiratory panel results since the M. cynos tuf 456 
assay went into production revealed similar findings. Specifically, M. cynos co-infections 457 
identified by us were comprised of up to 6 pathogens, including one or more of the following: 458 
canine parainfluenza virus, Bordetella bronchiseptica, beta-coronavirus, canine pneumovirus, 459 
canine distemper virus, influenza A virus, and/or canine adenovirus. 460 
In conclusion, this report describes the first comprehensive validation of an open-source 461 
assay for M. cynos. With its publication, the authors hope to promote assay harmonization in 462 
veterinary diagnostics in order to facilitate surveillance and the use of validated assays.  463 
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